Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2002

View Archived Issues

Opioid painkillers in development at Pain Therapeutics lack drug tolerance and dependence

Safety and pharmacokinetics of single infusions of CJC-1008 evaluated in healthy volunteers

New guidelines for unstable angina and NSTEMI Rx

Pharmacological effects of a new cannabinoid agonist described at APS meeting

Long-term intrathecal ziconotide associated with improved sleep and daily life

Inhaled morphine superior to oral morphine for cancer breakthrough pain

Long-lasting oral antithrombotic efficacy demonstrated for AT-1015 in rat model

Chymase inhibition improves outcome in hamsters with myocardial infarction

FDA approval for new formulation of Visicol

Deltagen's drug target DT021I enters development program for inflammatory diseases

Aventis to study prolonged administration of Lovenox in prophylaxis of venous thromboembolism

Millennium and PAION collaborate on development of MLN-519 for stroke

KF-66854: a new prokinetic agent that acts via 5-HT4 receptors

Ricerca to produce CEP-7055 for Cephalon

Optimal treatment regimen for Vasogen's immune modulation therapy identified

Seattle Genetics licenses monoclonal antibodies from Mabtech

Merck & Co. to submit expanded NDA for Arcoxia

Selective nitric oxide synthase inhibitors patented by Pharmacia

Salus to collaborate with PARI to develop inhaled antibiotic

Potential new analgesic agent with an improved side effect profile under study at UCB

Merck & Co. reports new factor Xa and factor VIIa inhibitors

NeoRx updates progress and plans for targeted therapeutic products

GSK-3beta inhibitors identified at Roche

Compounds for the treatment of obesity and other disorders reported by Roche and Vernalis

Imidazole derivatives and their uses described by Pfizer in a recent patent

Isis reports novel antibacterial compounds and their use

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...